Punto Health has raised $2.7 million in seed funding to expand its technology platform focused on earlier detection and continuous, personalized support for people experiencing cognitive decline. The company, led by co-founder and CEO Anna Muñoz Farré, said the financing will be used to scale the product, hire across London and Barcelona, and extend access to proactive dementia care for more families.
In announcing the round, Muñoz Farré described dementia as “one of the biggest health challenges of our time,” noting that care today is often reactive and fragmented, leaving families with limited guidance and ongoing emotional strain. Punto Health’s approach is built around shifting cognitive care toward earlier identification and day-to-day support that is easier for patients, carers, and clinicians to use consistently.
The platform combines speech-based digital biomarkers with personalized daily care and clinician dashboards in what the company describes as a connected ecosystem designed to make proactive cognitive support more routine. Punto Health said it has spent the past year co-designing and validating its solution with clinical and health system partners, including Ace Alzheimer Center Barcelona, North London NHS Foundation Trust, Oxleas NHS Foundation Trust, Hospital General de Granollers, Hospital del Mar, and Consorci Sanitari de l’Alt Penedès, and has reached more than 2,000 people during that work.
The company credited feedback from patients, carers, and clinicians as a central input into product development, shaping how the technology supports monitoring, guidance, and care coordination. Punto Health also highlighted a broad network of supporters and collaborators spanning clinical leaders, research partners, and startup ecosystem organizations as it moves into its next phase of growth.
The seed round included backing from Shilling VC, Plus Partners, Exceptional Ventures, HEARTFELT_, Fondo Bolsa Social, Abac Nest Ventures, Deuce Capital, and Lavender Ventures, according to the company.
